Bioventix PLC (LON:BVXP - Get Free Report) insider Bruce Hiscock purchased 24 shares of the stock in a transaction dated Friday, November 22nd. The stock was acquired at an average cost of GBX 3,822 ($48.12) per share, for a total transaction of £917.28 ($1,154.83).
Bruce Hiscock also recently made the following trade(s):
- On Wednesday, October 30th, Bruce Hiscock bought 300 shares of Bioventix stock. The shares were acquired at an average cost of GBX 3,330 ($41.92) per share, for a total transaction of £9,990 ($12,577.11).
Bioventix Trading Up 2.3 %
Shares of LON BVXP traded up GBX 84 ($1.06) during mid-day trading on Friday, hitting GBX 3,794 ($47.77). The company had a trading volume of 5,647 shares, compared to its average volume of 5,884. The stock's 50-day moving average price is GBX 3,770.97 and its 200-day moving average price is GBX 4,107.58. The company has a market capitalization of £198.05 million, a price-to-earnings ratio of 2,298.16 and a beta of 0.35. Bioventix PLC has a 1 year low of GBX 2,977 ($37.48) and a 1 year high of GBX 5,100 ($64.21).
Bioventix Increases Dividend
The company also recently announced a dividend, which was paid on Thursday, November 21st. Investors of record on Thursday, November 7th were issued a dividend of GBX 87 ($1.10) per share. This represents a yield of 2.4%. The ex-dividend date was Thursday, November 7th. This is a positive change from Bioventix's previous dividend of $68.00. Bioventix's dividend payout ratio is 9,693.25%.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
